retatrutide in spanish ESC 2024: improves lipid and cardiovascular risk profile Phase II trial Retatrutide | GLP-1R/GIPR/GCGR ligand |

doi: 10.1111/dme.12328 74 OnishiYNiemoellerEIkedaYTakagiHYabeDSeinoY

This weight regain is not due to medication "dependence" in the traditional sense, but rather reflects the underlying biology of obesity as a chronic condition

Importantly, these studies rarely measured GLP-1 levels as a mechanism, and the strains tested varied widely

The peptide GLP-1 is produced by the enteroendocrine L-cells of the small intestine as a cleavage product of the pre-proglucagon gene within minutes in response to oral glucose or fat

The FDA has no direct precedent for reviewing a glucagon agonist for chronic weight management

For some patients, 8 mg is the optimal maintenance dose